Patents Assigned to ULTUPHARMA AB
  • Patent number: 11981755
    Abstract: The present invention relates to novel compounds, which presents a peptide structure and an unexpected antibacterial effect even against certain multiresistant bacteria. The compounds may be cyclic peptides, sometimes depsipeptides, or non-ring-closed peptides, as defined by Formula (I). Further, the invention relates to the medical use of the herein claimed compounds, a method for the production of the compounds as well as a method of treatment including the compounds. In addition, the invention relates to a pharmaceutical preparation comprising one or more of the herein described and claimed compounds combined with suitable carrier(s) and/or adjuvant(s). Finally, the invention is the use of one or more of the claimed compounds in a method for decolonization of a surface of Gram-positive and/or Gram-negative bacteria.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: May 14, 2024
    Assignee: ULTUPHARMA AB
    Inventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord
  • Publication number: 20210269483
    Abstract: The present invention relates to novel compounds, which presents a peptide structure and an unexpected antibacterial effect even against certain multiresistant bacteria. The compounds may becyclic peptides, sometimes depsipeptides, ornon-ring-closed peptides, asdefined by Formula (I). Further, the invention relates to the medical use of the herein claimed compounds, a method for the production of the compounds as well as a method of treatment including the compounds. In addition, the invention relates to a pharmaceutical preparation comprising one or more of the herein described and claimed compounds combined with suitable carrier(s) and/or adjuvant(s). Finally, the invention is the use of one or more of the claimed compounds in a method for decolonization of a surface of Gram-positive and/or Gram-negative bacteria.
    Type: Application
    Filed: August 27, 2019
    Publication date: September 2, 2021
    Applicant: ULTUPHARMA AB
    Inventors: Bo ÖBERG, Anders BROBERG, Bengt GUSS, Jolanta LEVENFORS, Joakim BJERKETORP, Christina NORD
  • Patent number: 10933048
    Abstract: The invention relates to compounds of Formula I, wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula I in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: March 2, 2021
    Assignee: Ultupharma AB
    Inventors: Anders Broberg, Pierre Andersson, Jolanta Levenfors, Joakim Bjerketorp, Christer Sahlberg
  • Patent number: 10828317
    Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: November 10, 2020
    Assignee: Ultupharma AB
    Inventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord
  • Patent number: 10828316
    Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be trimethoprim or a compound comprising trimethoprim, such as trimethoprim-sulfa.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 10, 2020
    Assignee: ULTUPHARMA AB
    Inventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord
  • Publication number: 20200138777
    Abstract: The invention relates to compounds of Formula I, wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula I in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.
    Type: Application
    Filed: October 2, 2019
    Publication date: May 7, 2020
    Applicant: ULTUPHARMA AB
    Inventors: Anders BROBERG, Pierre ANDERSSON, Jolanta LEVENFORS, Joakim BJERKETORP, Christer SAHLBERG
  • Patent number: 10471043
    Abstract: The invention relates to compounds of Formula (I), wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula (I) in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 12, 2019
    Assignee: Ultupharma AB
    Inventors: Anders Broberg, Pierre Andersson, Jolanta Levenfors, Joakim Bjerketorp, Christer Sahlberg
  • Publication number: 20180360802
    Abstract: The invention relates to compounds of Formula (I), wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula (I) in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 20, 2018
    Applicant: ULTUPHARMA AB
    Inventors: Anders BROBERG, Pierre ANDERSSON, Jolanta LEVENFORS, Joakim BJERKETORP, Christer SAHLBERG
  • Publication number: 20180325934
    Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be trimethoprim or a compound comprising trimethoprim, such as trimethoprim-sulfa.
    Type: Application
    Filed: January 27, 2017
    Publication date: November 15, 2018
    Applicant: ULTUPHARMA AB
    Inventors: Bo ÖBERG, Anders BROBERG, Bengt GUSS, Jolanta LEVENFORS, Joakim BJERKETORP, Christina NORD
  • Publication number: 20180280417
    Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.
    Type: Application
    Filed: May 24, 2018
    Publication date: October 4, 2018
    Applicant: ULTUPHARMA AB
    Inventors: Bo ÖBERG, Anders BROBERG, Bengt GUSS, Jolanta LEVENFORS, Joakim BJERKETORP, Christina NORD